최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
DataON 바로가기다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
Edison 바로가기다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
Kafe 바로가기국가/구분 | United States(US) Patent 등록 |
---|---|
국제특허분류(IPC7판) |
|
출원번호 | US-0611172 (2009-11-03) |
등록번호 | US-9421330 (2016-08-23) |
발명자 / 주소 |
|
출원인 / 주소 |
|
대리인 / 주소 |
|
인용정보 | 피인용 횟수 : 0 인용 특허 : 344 |
A system which includes a pressurizing mechanism to pressurize a fluid including a contrast enhancement agent for delivery to a patient and a control system in operative connection with the pressurizing mechanism. The control system includes a system to adjust control of fluid injection based upon a
A system which includes a pressurizing mechanism to pressurize a fluid including a contrast enhancement agent for delivery to a patient and a control system in operative connection with the pressurizing mechanism. The control system includes a system to adjust control of fluid injection based upon a measurement of renal function of the patient.
1. A system comprising: a pressurizing mechanism to pressurize a fluid comprising a contrast enhancement agent for delivery to a patient; anda control system in operative connection with the pressurizing mechanism, the control system comprising: a protocol generation system to generate an initial in
1. A system comprising: a pressurizing mechanism to pressurize a fluid comprising a contrast enhancement agent for delivery to a patient; anda control system in operative connection with the pressurizing mechanism, the control system comprising: a protocol generation system to generate an initial injection protocol comprising a set of injection parameters defining a total amount of the contrast enhancement agent to be delivered to the patient according to the initial injection protocol; anda contrast induced nephropathy risk assessment system to adjust one or more of the injection parameters of the initial injection protocol based at least in part upon a measurement of renal function of the patient and an assessment of a risk of contrast induced nephropathy,wherein the assessment of the risk of contrast induced nephropathy is determined, at least in part, on an analysis of the patient's glomerular filtration rate, andwherein adjusting one or more injection parameters of the initial injection protocol comprises determining a recommended maximum amount of the contrast enhancement agent to be delivered to the patient, comparing the recommended maximum amount of the contrast enhancement agent to the total amount of the contrast enhancement agent to be delivered to the patient according to the initial injection protocol, and presenting, on a display screen associated with the system, a reduction factor by which the total amount of the contrast enhancement agent to be delivered to the patient according to the initial injection protocol should be reduced. 2. The system of claim 1, wherein the control system is operative to constrain fluid injection to reduce a likelihood of contrast induced nephropathy. 3. The system of claim 1, comprising: an analyzing system to analyze a time enhancement curve resulting from injection of the fluid comprising the contrast enhancement agent to provide the measurement of renal function. 4. The system of claim 3, wherein the analyzing system is in operative connection with the control system such that injection of the fluid into the patient can be controlled to reduce the likelihood of contrast induced nephropathy based, at least in part, on the analysis of the time enhancement curve. 5. The system of claim 1, wherein the control system is operative to control injection of the fluid into the patient to reduce the likelihood of contrast induced nephropathy based, at least in part, on input of patient specific parameters. 6. The system of claim 1, further comprising: an input system for input of patient parameters associated with renal function, the input system being in operative connection with the control system. 7. The system of claim 6, wherein the patient parameters comprise at least one of age, body mass index, sex, serum creatinine level in the blood plasma, and blood urea nitrogen. 8. The system of claim 1, comprising a system to determine a therapy for the patient after delivery of the fluid to the patient if the patient is determined to be at risk of contrast induced nephropathy. 9. The system of claim 8, wherein the therapy comprises a hydration therapy. 10. The system of claim 8, wherein the determination of the therapy is based, at least in part, on analysis of a time enhancement curve resulting from injection of the fluid comprising the contrast enhancement agent to provide the measurement of renal function. 11. The system of claim 1, wherein the control system is in communicative connection with a contrast induced nephropathy therapy system. 12. The system of claim 11, wherein the therapy system comprises a pump for introducing therapeutic fluids. 13. The system of claim 1, wherein adjusting one or more injection parameters further comprises adjusting at least one of a flow rate and an injection duration so that the contrast enhancement agent delivered in the injection does not exceed the recommended maximum amount of the contrast enhancement agent. 14. A method of performing an imaging procedure, the method comprising: generating an initial injection protocol on a system, the initial injection protocol comprising a set of injection parameters defining a total amount of a contrast enhancement agent to be delivered to a patient according to the initial injection protocol;adjusting one or more injection parameters of the initial injection protocol based at least in part upon a determination of renal function of the patient and an assessment of a risk of contrast induced nephropathy, wherein the assessment of the risk of contrast induced nephropathy is determined, at least in part, on an analysis of the patient's glomerular filtration rate, and wherein adjusting one or more injection parameters of the initial injection protocol comprises determining a recommended maximum amount of the contrast enhancement agent to be delivered to the patient, comparing the recommended maximum amount of the contrast enhancement agent to the total amount of the contrast enhancement agent to be delivered to the patient according to the initial injection protocol, and presenting, on a display screen associated with the system, a reduction factor by which the total amount of the contrast enhancement agent to be delivered to the patient according to the initial injection protocol should be reduced;generating a revised injection protocol based, at least in part, on the reduction factor and the initial injection protocol;delivering the contrast enhancement agent to the patient according to the revised injection protocol; andimaging at least a portion of the patient. 15. The method of claim 14, wherein the renal function of the patient is determined, at least in part, based upon at least one patient parameter. 16. The method of claim 15, wherein the patient parameter is at least one of age, body mass index, sex, creatinine level, and blood urea nitrogen. 17. The method of claim 14, wherein the renal function of the patient is determined, at least in part, based upon analysis of a time enhancement curve of the contrast enhancement agent in at least one region of interest of the patient. 18. The method of claim 14, further comprising: determining a therapy for the patient after delivery of the fluid to the patient if the patient is determined to be at risk of contrast induced nephropathy. 19. The method of claim 18, wherein the determination of the therapy is based, at least in part, on analysis of a time enhancement curve resulting from injection of the fluid comprising the contrast enhancement agent to determine a measurement of renal function. 20. The method of claim 18, wherein the therapy comprises at least one of hydration therapy and introduction of at least one nephroprotective agent. 21. The method of claim 14, further comprising: determining a therapy for the patient before delivery of the fluid to the patient if the patient is determined to be at risk of contrast induced nephropathy. 22. The method of claim 14, wherein adjusting one or more injection parameters further comprises adjusting at least one of a flow rate and an injection duration so that the contrast enhancement agent delivered in the injection does not exceed the recommended maximum amount of the contrast enhancement agent.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.